Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1655 - Comparison of venous thromboembolism risk assessment models in patients receiving chemotherapy

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Konrad Talasiewicz

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

K. Talasiewicz, P. Ozdowska, B. Milanowska, K. Gepner, B. Jagielska

Author affiliations

  • Department Of Oncology Diagnostics, Cardioncology And Palliative Medicine, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1655

Background

Venous thromboembolic events (VTEs) remain one of the most common causes of morbidity and mortality in cancer patients. Various risk scores were developed to help oncologists in the decision-makingprocess relating to VTE in this challenging group of patients.

Methods

We retrospectively analyzed a group of 124 cancer patients diagnosed with VTE between September 2012 and June 2017 in M.Sklodowska-Curie Memorial Cancer Center and Institute, Warsaw, Poland and selected patients receiving chemotherapy (n = 72). We compared the patients KHORANA, PROTECHT and CONKO scores in order to determine which of them would be more precise in terms of VTE prediction during chemotherapy. Statistical analysis was made using descriptive statistics, differences between scales were tested using chi-squared test applying Bonferroni correction.

Results

VTE’s were observed mainly during chemotherapy treatment (n = 72, 58.1%). VTE’s occurred significantly more frequently in patients who received Cisplatin- or Gemcitabine- basedchemotherapy (p < 0,05). In 27 (21.8%) cases VTE was the first manifestation of the disease and/or appeared during the diagnostic process. Most of the patients (69,64% - 88,89% depending of the scale) were classified as having low/intermediate risk, without the potential need for thromboprohylaxis use. The PROTECHT score was the best indicator to discriminate between patients with high or low/intermediate risk, followed by the CONKO score and finally by the KHORANA score. The PROTECHT score more often assigned patients to the “high-risk group” and this difference was statistically significant comparing with the KHORANA score, p = 0,016 (Table).Table: 1723P

RiskKHORANAPROTECHTCONKO
N%N%N%
Low2129,17%1723,61%2636,11%
Intermediate4359,72%3345,83%3447,22%
High811,11%2230,56%1216,67%
chi210,99
df4
p0,0267
KHORANA vs. PROTECHTKHORANA vs. CONKOPROTECHT vs. CONKO
chi28,272,384,84
df222
p0,01600,30360,0889
Bonferroni0,04800,91080,2667

Conclusions

The PROTECHT score discriminated better between low- and high-risk patients and appeared to have the highest sensitivity. The implementation of VTE prophylaxis in patients assessed as high-risk patients, according to the PROTECHT score, could potentially prevent the largest amount of VTEs.

Clinical trial identification

Legal entity responsible for the study

Maria Sklodowska-Curie Memorial Cancer Center and Institute, Warsaw, Poland.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.